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Abstract 
AIM: This study aimed to observe the cyclooxygenase-2 expression and its correlation with tumour size and 
lymph node involvement in nasopharyngeal carcinoma. 
METHODS: This study was cross-sectional, that enrolled 126 samples diagnosed with nasopharyngeal carcinoma 
in Haji Adam Malik General Hospital, Medan, Indonesia which fulfilled the inclusion criteria. 
RESULTS: Based on this study, we found that the age peak incidence of nasopharyngeal carcinoma patients 
about a 41-60-year-old group (57.1%), dominated by men (71.4%). Through histopathological examination, non-
keratinizing squamous cell carcinoma is the most predominant type (79.4%). We also found T3 is the most 
prevalent primary tumour size (32.5%) with prominent lymph node involvement N3 (45.2%), and stage IV (54.8%). 
Cyclooxygenase-2 overexpression is prevalent among nonkeratinizing squamous cell carcinoma (81.1%), T3 
primary tumour size (41.1%), N3 node involvement (60.0%), and IV clinical stage (71.6%). In addition, we found a 
significant relationship between cyclooxygenase-2 expressions towards tumor size (p < 0.001) and lymph node 
involvement (p < 0.001) in nasopharyngeal carcinoma. 
CONCLUSION: It is proved that the overexpression of cyclooxygenase-2 will increase the susceptibility of 
nasopharyngeal carcinoma patients having advanced primary tumour size and lymph node involvement. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Nasopharyngeal carcinoma (NPC) is a 
malignancy originating from nasopharyngeal epithelial 
cells [1]. NPC incidence is dominated by Asia 
population, especially South China and South- East 
Asia [2]. In Indonesia, there are approximately 6.2 of 
100,000 people diagnosed with NPC. Based on the 
data in 2008, NPC becomes the fifth leading cause of 
cancer mortality with annual incidence 13,000 [3]. 
Cyclopentane-fatty acid derivatives, largely 
known as prostaglandin, are produced in the 
human cell. It is well-known as a chemical mediator 
of inflammation. Meanwhile, COX or prostaglandin 
endoperoxidase synthase is an enzyme involved in 
the formation of prostaglandin [4], [5]. COX has two 
isoforms: COX-1 and COX-2. For maintaining 
homeostasis, COX-1 is expressed by most cells. In 
contrast, COX-2 expression related to some 
pathological conditions, particularly in malignancy. 
COX-2 can induce angiogenesis and inhibit apoptosis. 
Also, COX-2 has a certain role in resistance to 
cancer immunotherapy [6], [7], [8], [9]. COX-2 
converts arachidonic acid into five major 
prostanoids: PGE2, PGD2, PGI2 (prostacyclin), 
PGF2α, and thromboxane A2 (TXA2) [10], [11]. 
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A number of studies have shown that COX-2 
will induce angiogenesis by several mechanisms, such 
as (1) VEGF, it has been explained in the previous 
section; (2) formation of eicosanoid product (TXA2, 
PGI2, PGE2), it will directly stimulate endothelial 
formation, growth, and migration; (3) endothelial cell 
will be less susceptible to apoptotic by elevation anti-
apoptotic Bcl-2 protein expression and activation of 
the  PI3K-Akt pathway; (4) matrix metalloproteinase 
(MMP) will increase its expression, related to 
vascular invasion; (5) function of angiogenic protein 
will increase αvβ3 integrin; (6) IL-12 expression as 
angiogenesis inhibitor will decrease [2], [12], [13], [14], 
[15], [16], [17]. In another side the effect of COX-2 on 
angiogenesis, the effect of COX-2 on lymph nodes 
involvement still poorly understood but there is an 
opinion that said macrophages had been suggested 
as a major source of lymphangiogenic growth factor 
appeared chronic inflammatory lesions [18]. 
Our study will show that PGE2 expression, 
the only one prostanoid, increase as a response to 
the COX-2 overexpression. COX-2/PGE2 pathway 
proved its importance in stimulating myeloid-derived 
suppressor cells production. Myeloid cells can 
support tumour growth by suppressing immune 
function and induce angiogenesis [19], [20], [21], 
[22]. COX or prostaglandin endoperoxidase synthase 
is an enzyme involved in prostaglandin formation, and 
its existence is related to inflammation and tumour 
growth.  
We looked at the COX-2 overexpression 
and compared them COX has two isoforms: COX-
1 and COX-2. COX-2 is associated with 
prostaglandin synthesis in inflammatory tissues and 
neoplastic processes. In the previous study, COX-2 
overexpression is well-documented involved in 
oncogenesis for certain malignancy, especially NPC 
[6], [23], [24], [25]. 
 
 
Material and Methods 
 
In this study researchers aimed to observe the 
cyclooxygenase-2 expression and its correlation with 
tumour size and lymph node involvement in 
nasopharyngeal carcinoma. This cross-sectional 
study enrolled 126 samples diagnosed with 
nasopharyngeal carcinoma in Haji Adam Malik 
General Hospital, Medan, Indonesia which fulfilled the 
inclusion criteria. This study was conducted to analyse 
the correlation between cyclooxygenase-2 
overexpression with tumour size and lymph node 
involvement in nasopharyngeal carcinoma. It was 
also expected that it could be used as one of the 
factors that affect the prognosis in patients with 
nasopharyngeal carcinoma. 
This cross-sectional study conducted in Haji 
Adam Malik General Hospital and pathology 
department, Medical Faculty of Universitas Sumatera 
Utara (USU), Medan, Indonesia. This study enrolled 
126 patients diagnosed with NPC by doing 
anamnesis, physical examination, imaging studies, 
and histopathological examination. 
Then, the samples had to fulfil the 
inclusion criteria, such as NPC patient diagnosed 
by histopathological examination and also had never 
undergone radiotherapy, chemotherapy, or in 
combination. If the paraffin blocks were not in good 
condition and the patients were positive with other 
malignancy, the subject would be excluded from the 
study. We used non-probability consecutive sampling 
to avoid tendency and bias and provided the 
demographic data including gender, age, and some 
variables related to the samples, condition, including 
histopathologic type (based on World Health 
Organization/WHO). 
While primary tumour size (T), lymph node 
involvement (N), and clinical staging were listed 
based on the American Joint Committee on Cancer 
(AJCC) 2010 classification. Tissue sections from 
paraffin block embedded NPC biopsies were 
stained with Genetex Human COX-2 Antibody. 
Slides were incubated with t h e  universal 
peroxidase-labelled polymer (PolyVuePlus) 
HRP/DAB Detection System and counterstained with 
hematoxylin. Then, the result classified into four 
categories by using broad and intensity score, such 
as 0 = negative, 1 = < 10% of the cell stained or 
weak-stained, 2 = 10-50% of cells stained or 
moderate-stained, 3 = > 50% of cells stained or 
strong-stained. COX-2 immunostaining expression 
on tissue sections of paraffin block NPC biopsies can 
be seen in Figure 1. 
 
Figure 1: Strong cytoplasmic expression of COX-2 in non-
keratinizing squamous cell nasopharyngeal carcinoma (x 400) 
 
Eventually, the final score was obtained by 
multiplying broad scores with intensity scores. The 
score was called as immunoreactive scores, 4 or 
more defined as positive or overexpression. 
Histopathological examination and the process 
related to immunohistochemical staining were done 
by three professional pathologists. 
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The statistical analysis was done by using 
SPSS 16.0 software (SPSS, Chicago, IL). 
Demographic data were listed in a univariate variable. 
Then, bivariate analysis was performed using chi-
square (
2
) test to determine the relationship 
between COX-2 overexpression with primary tumour 
size and lymph node involvement in NPC. This study 
also had been approved by the Health Research 
Ethical Committee of Medical Faculty of Universitas 
Sumatera Utara, Medan, Indonesia. 
 
 
Results 
 
This study was conducted on 126 NPC 
patients who fulfilled the inclusion criteria. The highest 
prevalence of NPC was found in the age group of IV 
to VI decades (57.1%), dominated by males (71.4%) 
with non-keratinizing squamous cell carcinoma 
(79.4%), primary tumor size T3 (32.5%), lymph node 
involvement N3 (45.2%), and clinical stadium IV 
(54.8%). Based on immunohistochemical 
examination overexpression of COX-2 were also 
found in nonkeratinizing squamous cell carcinoma, 
primary tumour size T3, lymph node involvement N3, 
and clinical stadium IV. Based on the results of this 
study, we found a significant relationship between 
COX-2 expression with tumour size and enlarged 
lymph nodes with a value of p < 0.001. 
Table 1: COX-2 overexpression frequency based on 
histopathology type, lymph node involvement (N) frequency, 
and clinical staging 
Type  COX-2 Expression   
Over-expression % Negative % P** 
Histopathology     0.253 
Keratinizing SCC* 7 (7.4) 1 (12.5)  
Non-keratinizing SCC* 77 (81.1) 23 (23)  
Undifferentiated carcinoma 11 (11.6) 7 (38.9)  
Primary Tumor Size (T)     0.000 
T1 5 (5.3) 20 (64.5)  
T2 24 (25.3) 8 (25.8)  
T3 39 (41.1) 2 (6.5)  
T4 27 (28.4) 1 (3.2)  
Lymph node involvement 
(N) 
    0.000 
N0 9 (9.5) 18 (58.1)  
N1 14 (14.7) 5 (16.1)  
N2 15 (15.8) 8 (25.8)  
N3 57 (60.0) 0 (0.0)  
Clinical staging     0.000 
I 2 (2.1) 15 (48.4)  
II 7 (7.4) 9 (29.0)  
III 18 (18.9) 6 (19.4)  
IV 68 (71.6) 1 (3.2)  
*SCC: Squamous Cell Carcinoma 
**p: P-value 
 
 
 
Discussion 
 
In our study, a positive correlation between 
COX-2 overexpression with primary tumour size and 
lymph node involvement was proved in NPC. It 
explains COX-2 overexpression is more common in 
advanced primary tumour size and lymph node 
involvement. Bin Yang et al., also discovered the 
same result related to COX-2 overexpression and 
malignant process, including metastasis [26]. A study 
conducted by Gui Yang et al., also found that COX-2 
and advanced clinical stage of NPC are positively 
correlated (OR 5.39; 95% CI: 3.79-7.66) [27]. Also, 
One study conducted by Li et al. found by using 
nasopharyngeal carcinoma cell lines treated with 
nonsteroid anti-inflammatory drugs (NSAIDs), 
particularly celecoxib, invasion, and migration will 
decrease through suppression of MMP-2 and -9 
activity [28]. Fendri et al., also discovered the similar 
result related to COX-2 overexpression that There 
was a significant association between COX-2 
expression with lymph node involvement (N+) in 
NPC patients with p < 0.0001 [29]. 
Besides VEGF, Epidermal growth factors 
(EGF) also play an important role in tumour 
proliferation and invasion. Ross found that COX-2 
overexpression occurred in 79% of NPC patients, 
and it related to EGFR status but not with latent 
membrane protein (LMP) -1 or inducible NOS. 
Meanwhile, Tan K-B prevailed that COX-2 might be 
involved in the multistep process of NPC 
carcinogenesis since the COX-2 expression is more 
common in a dysplastic nasopharyngeal cell [30], 
[31]. It is also stated by Kwong et al. which enrolled 53 
NPC patients, all patients who had intense staining 
for COX-2 were dysplastic [32]. Many clinical studies 
have shown that COX-2 induces angiogenesis, but 
there is no evidence to prove the relationship between 
COX-2 and lymph node involvement although many 
previous studies suggested that expression of COX-2 
correlated with lymph node metastasis [18]. 
Also, a prognostic study conducted by Pan et 
al. uncovered that survival rate, including overall 
survival, disease-free survival, locoregional control, 
and distant metastasis-free survival are also related to 
COX-2 overexpression. Chen et al. conducted a 
study in T4 NPC patients treated with radiation 
therapy, 5-year survival rates for patients who 
have COX-2 overexpression was 27% compared 
with 60% in low COX-2 expression group. 
Furthermore, Xinhua et al., also stated that COX-2 
might be used to predict prognosis, particularly local 
recurrence and distant metastasis [33], [34], [35]. 
Prognostic study related to COX-2 overexpression 
was evident in many cancer one of them is glottis 
cancer, COX-2 overexpression related to more 
aggressive tumour and low survival rate [36], [37], 
[38]. Otherwise, Long et al., and Y. J. Kim et al. found 
a contradictive result in our study. By using smaller 
sample sizes, both studies concluded that COX-2 
expression and tumour size did not correlate [39], 
[40]. 
Our study provided evidence that t h e  
correlation between COX-2 overexpression with 
primary tumour size and lymph node involvement 
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are significant (p < 0.001). The COX-2 expression 
will increase as the tumor size increases. COX-2 
overexpression is one of the tumor lymphangigenesis 
factors. Also, COX-2 contributes in the process of 
carcinogenesis, and it allows COX-2 to be used as a 
therapeutic target in the future for nasopharyngeal 
carcinoma. 
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